Advisor Publishes Book on Hyperbaric Oxygenation for Stroke & Alzheimer's

BOSTON, MASSACHUSETTS, June 27, 2024 -- BIOXYTRAN, INC. (OTCQB: BIXT), a company focused on developing drugs for stroke and Alzheimer's disease, has announced the publication of a significant book by its Science Advisor, Prof. Avraham Mayevsky. Titled "Hyperbaric Oxygenation Mitochondrial Activity and Brain Physiological Functions," the book is available in both eBook and Hardcover formats from the publisher Springer.

The book is closely associated with Bioxytran’s Hypoxia platform technology, which utilizes the MDX Viewer, an FDA-approved device. This device is designed to measure tissue oxygenation by assessing the consumption of oxygen molecules at the cellular level. The MDX Viewer outputs the Brain Metabolic Score (BMS), which plays a crucial role in the approval process of Bioxytran’s acellular oxygen carrier (AOC) molecule, BXT-25.

Bioxytran plans to use BXT-25 in clinical trials targeting patients with ischemic stroke and Alzheimer's disease. The intention is to replace traditional hyperbaric oxygen treatment (HBOT) with BXT-25, which is expected to oxygenate the brain more effectively. 

Prof. Mayevsky's book provides a comprehensive analysis of the effects of hyperbaric oxygen on brain functions, including mitochondrial activity. The MDX Viewer, frequently referenced throughout the book, has been pivotal in understanding the relationship between oxygenation and cerebral functions in the context of hyperbaric oxygenation treatment. 

The book also delves into the biochemical and physiological responses of the brain to hyperbaric oxygen treatment, highlighting its influence on mitochondrial activity, which is vital for energy production. Evidence presented in the book suggests that hyperbaric oxygen therapy can enhance cerebral blood flow and tissue oxygenation, ultimately benefiting brain function and performance.

Bioxytran, Inc. is a clinical stage biotechnology firm committed to developing innovative treatments for stroke and Alzheimer's disease. Their approach involves delivering oxygen using a molecule significantly smaller than a red blood cell, potentially revolutionizing the way these conditions are treated.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!